Physiogenex news

Physiogenex to attend the 2012 ADA annual meeting, Philadelphia, USA, June 8-12

Fri, 11 May 2012 00:00:00 +0200

Physiogenex to present at 80th European Atherosclerosis Society Congress, 25-28 May 2012, Italy.

Tue, 24 Apr 2012 00:00:00 +0200

Dr François Briand will present a poster entitled: "Berberine increases LDL-cholesteryl ester catabolism and stimulates LDL-derived cholesterol fecal excretion in hyperlipidemic hamsters".

Physiogenex to attend the European Congress on Obesity in Lyon, France, May 9-12, 2012

Thu, 12 Apr 2012 00:00:00 +0200

The Cardiometabolic hub is launched!

Thu, 29 Mar 2012 00:00:00 +0200

The cardiometabolic hub is a consortium of highly specialized contract research organizations that pool their scientific expertises, preclinical and clinical skills and technical resources to provide outstanding research services and consulting for pharmaceutical, biotechnology and nutraceutical companies worldwide.

Physiogenex to attend Diabetes summit in Boston, USA, April 19-20, 2012

Thu, 22 Mar 2012 00:00:00 +0100

High-fat and fructose intake induces insulin resistance, dyslipidemia, and liver steatosis and alters in vivo macrophage-to-feces reverse cholesterol transport in hamsters.

Thu, 22 Mar 2012 00:00:00 +0100

Dr François Briand, Head of Diabetic Dyslipidemia, and Physiogenex team unveil the results of a study in a hamster model of metabolic syndrome.

Sitagliptin promotes macrophage-to-feces RCT in obese insulin resistant CETP-apoB100 transgenic mice.

Fri, 03 Feb 2012 00:00:00 +0100

Dr François Briand, Head of Diabetic Dyslipidemia, and Physiogenex team unveil the results of a new study that supports the potential of dipeptidyl peptidase-4 (DPP-4) inhibitors to promote Reverse Cholesterol Transport (RCT) through reduced intestinal cholesterol absorption.

CETP inhibitor torcetrapib promotes reverse cholesterol transport in obese insulin-resistant CETP-ApoB100 transgenic mice.

Thu, 29 Dec 2011 00:00:00 +0100

Dr François Briand, Head of Diabetic Dyslipidemia, and Physiogenex team unveils the results of a new study that supports the potential of CETP inhibitors to prevent cardiovascular risk like dyslipidemia, a major characteristic of type 2 diabetic patients.

Physiogenex to present at International Symposium on Atherosclerosis, 30 March - 1 April 2012, Australia.

Wed, 28 Dec 2011 00:00:00 +0100

Dr François Briand will present a poster on “Up-regulation of reverse cholesterol transport requires reduction of apoliprotein-E rich HDL levels in hyperlipidemic hamsters treated with CETP inhibitor torcetrapib.”

Physiogenex sponsors and presents scientific results at the DEUEL conference on Lipids, March 6 – 9, 2012, CA, USA.

Tue, 27 Dec 2011 00:00:00 +0100

Physiogenex is proud to partner this high-quality conference dealing with many aspects of lipid/lipoprotein metabolism.